Global Knee Replacement Implants Market: International Catalysts and Concerns: Expected to Decline at a CAGR of -0.5% to approximately $7.8bn in 2024

December 9, 2020

Global Knee Replacement Implants Market shows Global sales of knee replacement implants totaled approximately $7.9bn in 2019. During the forecast period covered by this report, the market is expected to decline at a CAGR of -0.5% to approximately $7.8bn in 2024. View the report here.

This medical market and technology report provides a comprehensive discussion of the global market for knee replacement implants. Markets covered by this analysis comprise the US, Japan, the five major European markets (France, Germany, Italy, Spain, and the UK), and the rest of world (RoW) markets, which includes all other countries.

Although the market suffered a significant setback during the early days of the COVID-19 pandemic, it is expected to continue to improve over the forecast period due to new knee replacement patients seeking treatment and surgeons playing catch-up with the backlog of patients who have deferred treatment.

Growth in the knee replacement market is generally influenced by an aging global population and increasing life expectancy.

This report provides the following useful information:

  • osteoarthritis prevalence data
  • knee replacement procedure volumes
  • an overview of knee replacement implant technology
  • products offered by leading manufacturers
  • in-depth market and competitive analyses.

Key Topics Covered:

1. Clinical Overview and Procedure Volumes

1.1 Indications for knee arthroplasty

1.2 Epidemiology

1.3 Types of knee arthroplasty

1.3.1 Unicondylar knee arthroplasty

1.3.2 Revision knee arthroplasty

1.4 Procedure volumes

1.5 Bibliography

2. Knee Replacement Implants Market

2.1 Market analysis

2.1.1 US reimbursement issues

2.1.2 International catalysts and concerns

2.2 Competitive analysis

2.3 Product trends

2.3.1 Leading products

2.4 Bibliography

Appendix: Company Listing

Global Knee Replacement Implants Market view here.

 More reports here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version